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Background:.Borrelia.miyamotoi.clusters.phyloge-
netically among relapsing fever borreliae, but is trans-
mitted by hard ticks. Recent recognition as a human 
pathogen has intensified research into its ecology and 
pathogenic potential. Aims: We aimed to provide a 
timely critical integrative evaluation of our knowledge 
on B. miyamotoi, to assess its public health relevance 
and guide future research. Methods: This narrative 
review used peer-reviewed literature in English from 
January 1994 to December 2018. Results: Borrelia 
miyamotoi occurs in the world’s northern hemisphere 
where it co-circulates with  B. burgdorferi  sensu lato, 
which causes Lyme disease. The two borreliae have 
overlapping vertebrate and tick hosts. While ticks 
serve as vectors for both species, they are also reser-
voirs for B. miyamotoi. Three B. miyamotoi genotypes 
are described, but further diversity is being recog-
nised. The lack of sufficient cultivable isolates and 
vertebrate models compromise investigation of human 
infection and its consequences. Our understanding 
mainly originates from limited case series. In these, 
human infections mostly present as influenza-like ill-
ness, with relapsing fever in sporadic cases and neu-
rological disease reported in immunocompromised 
patients. Unspecific clinical presentation, also occa-
sionally resulting from Lyme- or other co-infections, 
complicates diagnosis, likely contributing to under-
reporting. Diagnostics mainly employ PCR and serol-
ogy.  Borrelia miyamotoi  infections are treated with 
antimicrobials according to regimes used for Lyme 
disease. Conclusions: With co-infection of tick-borne 
pathogens being commonplace, diagnostic improve-
ments remain important. Developing in vivo models 
might allow more insight into human pathogenesis. 
Continued ecological and human case studies are 
key to better epidemiological understanding, guiding 
intervention strategies.
Introduction
Borrelia miyamotoi, which belongs to the relaps-
ing fever clade within the  Borrelia  genus, was first 
described in 1994 with its detection in  Ixodes persul-
catus  ticks in Japan [1]. It was named after Professor 
Kenji Miyamoto who initially reported this spirochaete 
from Hokkaido, Japan. Its potential to cause human 
disease was not realised until 2011 when Platonov and 
colleagues described a series of cases of  B. miyamo-
toi infection in Russia [2].
It is now established that this spirochaete has a global 
distribution and co-circulates with the related agent of 
Lyme borreliosis (Lyme disease),  B. burgdorferi  sensu 
lato (s.l.), which uses the same tick species as vec-
tors, albeit at a lower frequency [3-9]. Similar to the 
Lyme borreliae, where different tick species endemic 
to specific regions of the globe serve as vectors,  B. 
miyamotoi  is found in multiple tick species that reside 
constrained by compatible geo-ecological habitats 
[2-4,10-13].
The objectives of this review were threefold: (i) to col-
late the rapid expansion of research findings on B. miy-
amotoi and its ecological interactions; (ii) to review the 
public health significance of  B. miyamotoi  and to (iii) 
highlight knowledge gaps in our understanding of this 
microbe and its importance as a human pathogen, thus 
focussing direction for future research.
Methods
We performed a non-systematic narrative literature 
review. Literature searches were thus not fully exhaus-
tive. Reports relating to the search term ‘Borrelia 
miyamotoi’ published in English and indexed in bio-
medical databases including EBSCO (Academic Search 
Complete), Scopus and Science Direct were sought 
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(Figure 1). These dated from the first description 
of  B. miyamotoi  in January 1994 to December 2018. 
Duplicate records were removed and articles were fur-
ther screened, first by reading the titles and abstracts, 
then the full reports. Prioritisation to those papers 
that contributed original knowledge to our understand-
ing was given. Supplementary literature was used to 
further support discussions beyond primary searches 
where justifiable (Figure 1). 
Results
Epidemiology
Borrelia miyamotoi  is being increasingly documented 
from the world’s northern hemisphere. This spirochaete 
has been recorded in Canada as well on the east and 
west coasts of the United States (US). It has also been 
observed in numerous European countries (includ-
ing the Czech Republic, Denmark, Estonia, France, 
Germany, Netherlands, Norway, Poland, Romania, 
Sweden and Switzerland) as well as in Russia through 
to Japan [3,10,14,15].
Surveys to detect B. miyamotoi have tended to reflect 
local research interest rather than being systematic 
epidemiological studies. These have however 
established that endemic areas for B. miyamotoi overlap 
with those for Lyme borreliae (B. burgdorferi s.l.), and 
during tick surveys, specimens co-infected with both 
spirochaetes have been identified [4,11,16]. In several 
countries, prevalence studies based upon individual 
ticks infected with borreliae  have noted lower rates 
of ticks infected with  B. miyamotoi  than with Lyme-
associated borreliae [5,17].
Among 20 studies found in this review, from countries 
reporting clinical cases and B. miyamotoi prevalence in 
ticks, infection rates in ticks ranged from 0.02 to 6.4%, 
although most studies reported a range between 1 and 
2% (Table 1) [3,5,15,18,19]. Nevertheless, pockets of 
higher infection rates have been described. In Napa 
County, California, US, for example, 15.4% of adult 
ticks (10/65  I. pacificus) studied were infected with  B. 
miyamotoi  [3] compared with a background infection 
level of 1.4% (44/3,255) of nymphs of this same spe-
cies [19]. Moreover, in a study in Kurgan, Russia, 16% 
of ticks (26/162 I. persulcatus) were found infected [2]. 
These rates might reflect either hyperendemic areas or 
local efficient transmission events.
In some countries, such as Mongolia, where relatively 
high levels of tick infections with B. miyamotoi  (4.5%; 
48/1,069 I. persulcatus) have been detected, no human 
cases were reported [10]. This was similar in the town 
of Hannover, Germany, where a tick-infection preva-
lence of 8.9% (45/505  I. ricinus  ticks) was reported 
but no infections in people [20]. On the other hand, on 
Hokkaido Island, Japan, where, depending on the tick 
species, 2% (71/3,532 I. persulcatus) and 4.3% (5/117 I. 
pavlovskyi) of ticks were infected, human cases did 
occur [4]. Human cases were also observed in the 
Irkutsk region, Russia, where an overall 2.9% preva-
lence of tick infection has been estimated [21] (Table 
1). In Yekaterinburg and Izhervsk, where clinical cases 
were first described, tick (I. persulcatus) infection prev-
alence rates of 0.9% (4/442) and 6.3% (25/394) were 
respectively found. Estimated incidence of human 
infection with B. miyamotoi in Yekaterinburg is likely to 
be 1 per 100,000 per year, accounting for a quarter of 
tick-borne borreliosis cases within this province [2,22].
Phylogeny and diversity of Borrelia miyamotoi
The taxonomic definition of the genus  Borrelia  is 
currently debated with the suggestion that the 
Lyme disease associated members be removed 
from this genus, and instead be placed in a new 
genus,  Borreliella  [23]. This suggestion has not been 
met with universal approval, with some experts sug-
gesting this division is premature given the current 
discovery of new spirochaetes [24,25]. Borrelia miyamo-
toi clusters among the relapsing fever spirochaetes, but 
unlike these, resides alongside B. theileri and B. lones-
tari that are also transmitted by hard ticks (Figure 2).
Until recently, it was believed that B. miyamotoi fell into 
three geographically separated clades (genotypes), 
namely the Asian (or Siberian), European and American, 
(Figure 2, Table 2), transmitted by I. persulcatus/I. pav-
lovskyi (I. ovatus), I. ricinus and I. scapularis or I. pacifi-
cus, respectively [26,27].
However, as knowledge of this particular spirochaete 
increases, more diversity within the species is being 
recognised. A slight sequence variation was observed 
among the Asian clade based upon 16S sequence data, 
typified by strain Y14T1 from I. persulcatus ticks (Figure 
2) that revealed sequence divergence from other mem-
bers within this clade [10]. Similarly, in the US, diver-
gence was noted among sequence types of American B. 
miyamotoi associated with I. pacificus (Figure 2) [12,28]. 
Given the highly conserved nature of 16S, it is not gen-
erally considered a reliable marker for the delineation 
of borreliae [29], as such, the level of heterogeneity 
among these variants might be considerably more than 
that inferred from 16S data alone.
A potential fourth clade was recently described for 
strains found in I. ovatus ticks in Japan. These showed 
clear separation from the established sequence 
types for 16S rRNA (Figure 2) and the clade was fur-
ther confirmed using more discriminatory multilocus 
sequence typing (MLST) phylogenetic approaches [30]. 
Representatives of this potentially novel clade of  B. 
miyamotoi were carried by up to 0.6% of ticks collected 
from Honshu Island, but were absent from those ticks 
collected in Hokkaido, Japan [4,10].
Strains belonging to different genotypes of  B. miy-
amotoi have been observed to geographically overlap. 
Asian and European genotypes have been detected in 
Russia and Estonia [2,11]. In south-eastern Estonia, the 
Asian strains were detected in both I. persulcatus and I 
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ricinus while the European strains could only be found 
in I. ricinus [11].
The situation in Estonia also illustrates that a single 
tick species (e.g.  I. ricinus) can harbour several geno-
types [11], a phenomenon that has also been observed 
for  I. ovatus, which can be infected by both the Asian 
and the new variant genotype [10]. On the other hand, 
some genotypes have been found in multiple tick spe-
cies such as the American strain found in  I. scapula-
ris  and  I. dentatus  [31], with its close variant present 
in  I. pacificus  [12]. Furthermore, there are reports of 
Asian clade representatives of  B. miyamotoi  in other 
types of ticks such as  Haemaphysalis concinna  [13] 
and H. longicornis [32], but the ecological role of these 
species for maintaining this spirochaete has not been 
fully elucidated. Thus vector specificity may not be as 
strict as previous data suggested.
Ecology
In studies assessing single strains of  B. miyamo-
toi  and their associated tick species, the spirochaete 
has been detected among unfed larval ticks, suggest-
ing successful transovarial (i.e. vertical) transmission 
to successive generations of ticks. Thus, ticks should 
be considered as both vectors and reservoirs for  B. 
miyamotoi. Vertical transmission is estimated to have 
a frequency of less than 0.8 per tick generation, thus 
not sufficient to sustain  B. miyamotoi  for more than 
a few successive generations, in isolation of other 
transmission mechanisms [6,33]. That such mecha-
nisms are needed has gained further support from 
laboratory-based  in vivo  infection studies suggesting 
a decline of tick infection by  B. miyamotoi  during 
their development, through trans-stadial moults [34]. 
Prevalence studies conducted with different  B. miy-
amotoi  tick instars revealed lower infection rates 
among larvae than among nymphal and adult ticks 
(which had equivalent rates) [35]. The higher infection 
rates in nymphs and adults possibly result from infec-
tion of ticks by feeding (i.e. horizontal transmission) 
later in their life cycle. This contrasts with a staged 
infection rate by instar reported for  B. burgdorferi  s.l. 
[11,17], whereby infection may occur predominantly by 
horizontal transmission (i.e. feeding).
Similar to other borreliae, prevalence of  B. miyamo-
toi  appears to be amplified through infection of 
certain avian and rodent species. Varied small ver-
tebrate species have been shown to be competent 
reservoirs of infection by  B. miyamotoi  including 
mice (Apodemus  spp. and  Peromyscus  spp.), voles 
(Microtus  spp.,  Myodes glareolus, and  Microtus arva-
lis), chipmunks (Tamias sp.), squirrels (Sciuridae spp.), 
European hedgehogs (Erinaceus europaeus) and 
racoons (Procyon  spp.) [6-8,15,31,36-39]. Avian spe-
cies have not been extensively surveyed, but  B. miy-
amotoi  has been detected in blackbirds (Turdus 
merula), great tits (Parus major), common chiffchaff 
(Phylloscopus collybita), song thrush (Turdus philome-
los), European robin (Erithacus rubecula) and European 
greenfinch (Chloris chloris) albeit at low levels 0.6–
8% of avian-removed ticks [15,31,40]. A report from 
Tennessee, US describes a surprisingly high level of B. 
miyamotoi  infection among wild turkeys (Meleagris 
gallopavo) with 58% (35/60) birds sampled testing 
positive for  B. miyamotoi  [41]. These birds were heav-
ily infested with A. americanum ticks (70%; 42/60), but 
none of the ticks were positive for B. miyamotoi [41].
Furthermore, larger vertebrates have been found with 
evidence of infection such as wild boar [42,43] but their 
ecological significance remains unclear. Interestingly, 
deer have been suggested to amplify B. miyamotoi tick 
infection rates in the US [44] and representatives of the 
Asian genotype of  B. miyamotoi  have been recovered 
from infected deer in the far East [32]. These obser-
vations contrast with the Lyme borreliae, where deer 
are not competent species to enhance transmission to 
ticks during feeding. Nevertheless, it must be noted 
Figure 1
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Literature used was derived from sifting EBSCO, Science Direct 
and Scopus databases searching for ‘Borrelia miyamotoi’ from 
January 1994 through to December 2018.
a Additional supplementary information was included as indicated 
to support discussion points as required. This included 
information on the pathobiology of other relapsing fever 
species.
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that a study from Japan failed to demonstrate  B. miy-
amotoi  in deer, but instead reported another hard-tick 
vectored borrelial species resembling B. theileri and B. 
lonestari  [45] that had been previously reported from 
Japanese  Haemaphysalis  spp. ticks [46] and  H. lon-
gicornis  from China [32]. A role for deer was also not 
corroborated by a study from the Netherlands and the 
European genotype [15]. Because the various studies 
reported here were based upon different  B. miyamo-
toigenotypes, strain differences might explain the dif-
ferences observed for transmission efficiency following 
ticks feeding upon deer.
Relations between Borrelia 
miyamotoi and Borrelia burgdorferi s.l.
In vertebrates, co-infection with  B. miyamotoi  and  B. 
burgdorferi  has been recorded, but the probability 
of dual infection appears no greater than that which 
would be expected independently by chance [6].
In ticks however, it remains a question whether co-
infection happens at random or not. Some studies 
suggest that co-infection is more frequent than either 
infection alone [15]. Others however suggest that this 
happens by chance. For example, subsequent to a 
study finding 264/5,431 (4.9%)  B. burgdorferi  sensu 
stricto in nymphal  I. pacificus  ticks, a subset of 3,255 
ticks was retested for B. miyamotoi. A total of 44 (1.4%) 
ticks were infected  B. miyamotoi  alone, and only one 
single individual with  B. burgdorferi  sensu stricto 
was also found co-infected with  B. miyamotoi  [19,47]. 
On the other hand, among  I. scapularis  ticks from 
Midwestern US, Hamer et al. report a 2.1 times lower 
level of co-infection with  B. burgdorferi  and  B. miy-
amotoi (0.05% co-infection among 1,565 questing adult 
ticks) than expected by chance [48].
Tick surveillance demonstrates that B. burgdorferi  s.l. 
is more prevalent than B. miyamotoi, approximating to 
a ratio of 10:1 or greater in several studies [5,6,48,49]. 
This is intriguing given that an American study sug-
gests that both species infect ticks to equivalent levels 
achieving infection rates of around 2,000 spirochaetes 
for nymphs and 5,000 for adult ticks (sometimes higher 
in the case of  B. miyamotoi) [6]. A European study, 
which quantified by PCR B. miyamotoi  in feeding ticks 
removed from humans, even reported considerably 
higher borrelial tick loads by B. miyamotoi (mean count 
of 2.1 x 105) than by B. burgdorferi s.l. (with a mean of 
4.5 × 103 for B. afzelii and 2.7 × 103 for B. garinii) [49]. 
Thus, infection prevalence among ticks is higher for B. 
burgdorferi  s.l. [5,6,48,49], however,  B. miyamotoi-
infected ticks appear to have equivalent [6], or higher 
quantities of borreliae within their tissues [49].
The answer to why we observe higher prevalence for B. 
burgdorferi  s.l. compared with  B. miyamotoi  in ticks, 
might reside in the superior ability for B. burgdorferi to 
persist in the skin of its vertebrate host, potentially 
extending the window of transmission to other feeding 
ticks. The failure to detect B. miyamotoi  in the skin of 
erythema migrans patients corroborates this theory 
[15]. Moreover, studies of  Peromyscus leucopus  mice 
during  I. scapularis  nymphal questing times have 
shown that Lyme-associated borreliae resided in the 
skin of their host, while  B. miyamotoi  gave a higher 
blood burden with density counts five times higher 
than  B. burgdorferi  s.l [6]. While levels up to 251 spi-
rochaetes of  B. miyamotoi  per mL blood have been 
observed, persistence in blood within an infected 
vertebrate appears comparable to  B. burgdorferi  s.l. 
[6,50].
The sympatric overlap of  B. burgdorferi  s.l. and  B. 
miyamotoi  begs the question as to how these closely 
related spirochaetes might interact. Remarkably, the 
prevalence of  B. miyamotoi  infection in ticks appears 
indifferent to variations in the habitat type, or to 
ecological influences that impact upon the prevalence 
of  B. burgdorferi  s.l. [19]. As nutritional requirements 
are likely to overlap, is there antagonism between 
these species, indifference or a more synergistic 
relationship? Competitive interactions have not been 
explored per se, however, emerging data suggest 
that these species appear indifferent to each other. A 
study of shared small rodent hosts suggests different 
seasonal peaks of infection, with  B. burgdorferi  s.l. 
rodent infection peaking in spring and being driven 
by nymphs, whereas  B. miyamotoi  rodent infection 
being predominant in summertime through larval ticks 
[51,52]. This separation might provide a means for both 
spirochaetes to co-exist [6]. Indeed, transovarial tick 
transmission of  B. miyamotoi  enables larval ticks to 
be infectious for their subsequent hosts. In contrast, 
tick larvae harbouring  B. burgdorferi  s.l. are rarely 
reported, suggesting infrequent vertical transmission 
in  B. burgdorferi  s.l. Among field-collected larvae, a 
study found  B. burgdorferi  s.l. in 0.62% as opposed 
to 2% for B. miyamotoi  [53]. Some recent publications 
query whether previously reported low levels of  B. 
burgdorferi s.l. vertical transmission constituted in fact 
detection of B. miyamotoi [54,55].
Transmission to humans, magnitude of human 
infection and pathogenesis
Emerging evidence supports presence of  B. miyamo-
toi in tick salivary glands [34], with a study finding that 
over 88% of second generation progeny of infected  I. 
scapularis  nymphal ticks had  B. miyamotoi  in their 
salivary glands, as seen with other relapsing fever spi-
rochaetes in their soft tick vectors [56]. Experimental 
mouse (CD-1 outbred Mus musculus mice) transmission 
studies using ticks derived from a field collected 
population infected with the American strain of B. miy-
amotoi, have demonstrated 10% infection after 24hrs, 
rising to 31% at 48hrs and 63% by 72hrs [56]. Though 
not as rapid as the transmission of classical relapsing 
fever spirochaetes by their soft tick vectors [57], this 
demonstrates transmission of B. miyamotoi in the first 
day of tick attachment, contrasting with the days of 
attachment needed by Lyme borreliae to migrate from 
the tick midgut to salivary glands for transmission [57]. 
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In this respect, in humans, transmission efficiency has 
been estimated at 8.3% [58], based upon a cohort of 
24 persons bitten by PCR-positive ticks, of whom only 
two later developed compatible clinical disease [58]. 
By comparison, three of 68 (4.4%), humans bitten 
by B. burgdorferi s.l. infected ticks, developed disease 
(erythema migrans) [58,59].
In terms of the magnitude of human infections 
with  B. miyamotoi, this depends to some extent on 
the frequency of tick bites among people and on the 
prevalence of tick infection. Ixodid ticks are holarctic 
in distribution and assessments of tick bites vary by 
country and location. In the Netherlands, it was esti-
mated that tick bites amount to 71,980 per million 
inhabitants (2007) [60]. In the Irkutsk region in Russia 
2014, tick bites were estimated at 12,500 per million 
people [21]. The prevalence of infection among ticks 
ranges from 0.5 to 6% in many regions of the northern 
hemisphere. Taken together with a transmission rate of 
8.3% [58], it is likely that human infections are under-
estimated [61].
Table 1
Studies worldwide reporting Borrelia miyamotoi infections, with diagnostic methods, prevalence and human clinical signs, 
1994–2018
Location
Borrelia miyamotoi 
cases with 
reference (year of 
publication)
Percentage 
of cases 
among 
persons 
studied
Reported infection 
prevalence in ticks Clinical signs
Diagnostic 
method
References for 
prevalence in ticks and 
human cases
Russia
51/302 humans 
bitten by ticks 
(2011) [2]
16.9%
Ixodes ricinus 0.8% 
 
I. persulcatus 
2.9−10.5% 
 
I. pavlovski 6.4%
Fever, chills, sweating, 
headache, fatigue and 
vomiting (relapsing 
fever in 5)
PCR and 
serology [2,21,104,105]
Izhevsk, 
Russia
2/24 B. miyamotoi 
infected-tick bites 
developed disease 
(2015) [58]
8.3%
Fever, chills, sweating, 
headache, fatigue, 
nausea, vomiting, 
dizziness.
PCR and 
serology [58]
Yekaterinburg, 
Russia
71/459 tick-borne 
infection (including 
1a also with Lyme 
borreliosis) (2018) 
[22]
15.5% Clinical details not described.
PCR and 
serology [2,22]
China
14/984 patients 
with tick-borne 
infection (2018) [13]
1.4%
I. persulcatu s3% 
 
Hyaloma concinna 2.8%
Fever, headache, 
anorexia, asthenia, 
arthralgia
PCR [13]
Hokkaido, 
Japan
2a/408 Lyme 
borreliosis cases 
(2014) [75]
0.49%
I. persulcatus 1.6−2% 
 
I. pavlovski 4.3% 
 
I. ovatus 0.5%
Fever, myalgia, 
anorexia
PCR and 
serology [4,10,75]
Japan
12/459 suspected 
Lyme borreliosis 
(2018) [64]
2.6%
One case 
meningoencephalitis; 
clinical history not 
disclosed on remainder.
Serology [4,10,64]
Hokkaido, 
Japan
1 case study (2017) 
[80] NA
Fever, macular 
erythematous rash, 
low blood pressure, 
thrombocytopenia.
Serology [4,10,80]
Germany
1 case study 
suspected Lyme 
neuroborreliosis 
(2016) [72]
NA I. ricinus 1.2–2.4%
Lymphomatous 
meningitis 
(immunocompromised)
PCR, 
CXCL13 and 
microscopy
[3,5,72,82]
Netherlands 1 case study (2013) [73] NA
I. ricinus 2.1–3.6%
Meningoencephalitis 
(immunocompromised)
Microscopy, 
PCR and 
equivocal 
serology
[15,73,106,107]
Netherlands 1 case study (2018) [103] NA
Lymphadenopathy, 
leucopenia and 
thrombocytopenia 
(immunocompetent)
Serology [15,103]
United States
97/11,515 acute 
febrile patients 
(2015) [78]
0.84%
I. scapularis 0.02−3.1% 
 
I. pacificus 0.4−2%
Fever, chills, myalgia, 
arthralgia, headaches, 
neutropenia, 
thrombocytopenia
PCR [3,6,18,19,35,78,83,108]
NA: not applicable.
a Denotes dual-infected cases who also presented with erythema migrans lesions.
6 www.eurosurveillance.org
In Yekaterinburg Province, Russia in 2009, it was esti-
mated  B. miyamotoi  infections occur in 1 per 100,000 
inhabitants [2]. Studies from the Netherlands sug-
gest that some 36,000 humans are bitten each year 
by  B. miyamotoi  (European strain) infected ticks [9]. 
Serological studies from the US appear to corrobo-
rate human exposure [62,63]. Despite this, reports of 
human infections are comparatively few; for example, 
retrospective serological evaluation of sera from cases 
suspected for Lyme disease only detected 19 indige-
nous cases in Japan between 2013 and 2017 [64].
Borreliae as a group, are renowned for their ability to 
persist within humans. Relapsing fever Borrelia undergo 
an elaborate series of antigenic variation coupled 
with other mechanisms such as binding factor H and 
evading the components of the complement cascade, 
enabling their persistence in blood or their human host 
over time. Likewise,  B. miyamotoi  possesses variable 
membrane proteins (vmp) that could facilitate relapse 
with different antigenic variants [65], and has the abil-
ity to bind factor H and related proteins, thus evad-
ing host complement-mediated degradation [66-68]. 
Clinical reports of relapse with  B. miyamotoi  infection 
are described in the literature, however surprisingly, 
this appears less frequently than seen with classical 
relapsing fever infections [2,69].
The borreliae have proven neurotropism potential, 
using the nervous system as an immunologically 
protected niche enabling persistence in their verte-
brate host [70,71]. The precise mechanisms by which 
spirochaetes exploit this niche are poorly under-
stood, but animal studies have shown that relaps-
ing fever  Borrelia  can survive for 270 days within this 
site, thus enabling greater  in vivo  persistence [70]. 
Neurological sequelae have been a feature of infection 
among immunocompromised individuals (see clini-
cal presentations below) [72-74]. An  in vivo  infection 
model is urgently needed to unravel the pathogenesis 
of human  B. miyamotoi  infection. A severe combined 
immune deficiency (SCID) mouse model has been 
established [34], but has limitations to extrapolate to 
infection in immunocompetent humans.
Clinical presentation
Clinical cases have been reported from Europe, Japan 
[4,64,75], China [13], Russia [2] and the US [76-78]. 
Infection with  B. miyamotoi  does not present with 
obvious hallmark signs. Instead, patients present 
with fever accompanied by non-specific influenza-like 
symptoms, such as chills, fatigue, headache, myalgia 
and arthralgia (Table 1) [9].
Although  B. miyamotoi  clusters within the relapsing 
fever group of spirochaetes, cases with the character-
istic recurring febrile episodes interspersed with non-
febrile intervals that typify classical relapsing fever 
have only been described sporadically [2,79]. In these, 
up to three febrile episodes have been recorded [2], 
however this might be an underestimation given that 
patients are typically managed with antimicrobial ther-
apy upon diagnosis. A case who was retrospectively 
diagnosed following spontaneous recovery had a docu-
mented relapsing illness with two episodes, albeit with 
a lengthy 3-week afebrile period [69].
Furthermore, unlike relapsing fever spirochaetes, 
epistaxis, abortion, jaundice and major organ fail-
ure have not appeared as features of  B. miyamo-
toi  infection. Nevertheless, both  B. miyamotoi  and 
classical relapsing fever share fever, headaches, chills, 
myalgia, arthralgia, and nausea/vomiting.
Some differences in clinical presentation have been 
noted between US and Russian cases, particularly 
regarding the presence of thrombocytopenia docu-
mented in approximately half of American cases [78], 
but not reported from those in Russia. This differen-
tial clinical presentation may be an artefact given the 
recent description of thrombocytopenia in a Japanese 
clinical case infected with an Asian B. miyamotoi strain 
[80], akin to those reported from Russian cases.
In two studies, cases have been reported with ery-
thema migrans [75,78], however it is likely that these 
had concomitant infection with  B. burgdorferi  s.l., 
thus representing co-infections. Indeed, one of these 
studies retrospectively sought presence of B. miyamo-
toi  in sera from cases diagnosed with Lyme disease, 
whereas the other reported one case of erythema 
migrans among 51  B. miyamotoi  patients who had an 
overall 14% co-infection rate with B. burgdorferi  s.l. A 
larger study of 71 PCR-confirmed B. miyamotoi infected 
cases from Yekaterinburg, Russia, found only five of 
these cases with erythema migrans [22]. Analysis of 
blood for confirmation of pathogens disclosed that 
one case was co-infected with B. burgdorferi s.l., but it 
was concluded that the remaining cases with erythema 
migrans were realistically also co-infections given the 
poor sensitivity of PCR to detect Lyme disease using 
blood samples (as B. burgdorferi s.l. tends to be found 
in the skin) [22,49].
Borrelia miyamotoi, like other members of the borreliae 
have demonstrated their ability to result in neurologi-
cal sequelae with descriptions of meningoencephalitis, 
albeit among immunocompromised individuals [64,72-
74]. Unlike the acute febrile presentation described 
above, infections in these immunocompromised cases 
described to date, have shown a more insidious onset, 
often over several months. One case presented with 
memory deficits and disturbed gait, with lumbar punc-
ture revealing pleocytosis and raised cerebrospinal 
fluid (CSF) protein [73].
Diagnostics
For immunocompromised patients, diagnosis with 
microscopy has been used to a certain extent [72-74], 
sometimes combined with immunofluorescence [74]. 
For example, in three case reports on immunocom-
promised patients infected with  B. miyamotoi  [72-74], 
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spirochaetes in the CSF were retrospectively detected 
by microscopy in one case [73]. For the other two 
cases, B. miyamotoi was also identified by microscopy, 
albeit after concentration of the CSF sample and either 
Giemsa or acridine orange staining [72,74]. For all three 
cases, however, microscopy was complemented with 
PCR for diagnosis confirmation [72-74].
Generally, for overall patients, diagnostic approaches 
depend on the stage and duration of infection. During 
the acute phase of infection, the presence of the spiro-
chaete in blood and CSF can been demonstrated using 
PCR and microscopy. The success of such methods rap-
idly reduces from the fourth day of disease correlated 
with depletion in the spirochaetal blood counts [22]. 
Clinical reports of relapse are described in the litera-
ture [2,69]. If this occurs, it is likely that direct detec-
tion using PCR or microscopy might again be valuable. 
Use of concentration methods can improve the diag-
nostic sensitivity of these techniques [72,74,81]. Later 
in the clinical course, serology is the mainstay diag-
nostic option.
In terms of PCR/molecular diagnostics during acute 
stages of infection − and for assessment of non-human 
vertebrates or ticks −, real-time PCR assays for B. miy-
amotoi  based upon either 16S rDNA [6] or the flagel-
lin gene target have been described. The effectiveness 
of such assays for detection of the newly described B. 
miyamotoivariants nevertheless remains to be estab-
lished [82]. Given the sympatric nature of  B. miyamo-
toi and its closely related Lyme-associated borreliae, a 
logical strategy would be to utilise a multiplex assay 
able to screen for both pathogens simultaneously. A 
multiplex approach is also probably better suited to 
a diagnostic setting to avoid multistep methods and 
Figure 2
Strain diversity of Borrelia miyamotoi based upon 16S rRNA sequences
KU749376 B. miyamotoi 14T114 China I. persulcatus
KU749372 B. miyamotoi 15H532 China Human
KU749375 B. miyamotoi 14T52 China I. persulcatus
KU749374 B. miyamotoi 15H508 China Human
NR025861 B. miyamotoi HT31 Japan I. persulcatus
LC064032 B. miyamotoi Russia I. persulcatus
KU749373 B. miyamotoi 13T392 China I. persulcatus
AB900817 B. miyamotoi Y13T1 Japan I. persulcatus
JF951380 B. miyamotoi Vologda-07(1)-IP Russia I. persulcatus
LC164096 B. miyamotoi Y14T1 1 I. persulcatus
Asian clade including variant
LC164110 B. miyamotoi Y13T17 I. ovatus
LC164122 B. miyamotoi Y14T18 I. ovatus
New variant strains
KU196080 B. miyamotoi Sonom53 USA I. pacificus
AY024345 B. miyamotoi LB-2001 USA I. scapularis
JQ926185.1 B. miyamotoi USA Human CSF
American clade including variant
KJ412193 B. miyamotoi tick404 France I. ricinus
JF951385 B. miyamotoi Mos-08(1)-IR Russia I. ricinus
JF951383 B. miyamotoi Stavr-09(1)-IR Russia I. ricinus
KJ412199 B. miyamotoi rongeur215 France I. ricinus
KJ847049 B. miyamotoi 543(1) Cz Republic I. ricinus
LC136799 B. miyamotoi T177 Turkey I. ricinus
KP202175 B. miyamotoi Z155 Austria I. ricinus
European clade
KF569941 B. theileri KAT Mali Rh. geigyi
AY166715 B. lonestari USA A. americanum
Other hard tick relapsing fever spp.
NR102957 B. hermsii DAH USA
AF107367 B. recurrentis A1 Ethiopia P. humanus
Classical relapsing fever spp.
95
79
95
97
93
98
86
67
0.002
European, American and Asian clusters are demonstrated alongside newly described strains, using classical relapsing fever species and other 
hard tick borreliae as outgroups. The colours of the branches denote the different clades and highlight variant strains. Tree labels provide 
GenBank accession numbers; strain reference; country of origin and source of sequence. The tree was compiled using a neighbour-joining 
algorithm, with clusters assessed using the bootstrap test for stringency (1,000 replicates). The percentages of replicate trees in which the 
associated isolates clustered together are shown next to the branches. The tree is drawn to scale, with branch lengths in the same units 
as those of the evolutionary distances used to infer the phylogenetic tree. These units represent the number of base substitutions per site. 
Evolutionary analyses were conducted in MEGA7.
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reduce contamination risks that arise at each step. 
Some studies have suggested assays that differenti-
ate conditions with overlapping clinical presenting fea-
tures, such as B. miyamotoi infection and anaplasmosis 
[77] and have thus produced multiplex PCR assays to 
differentiate these infections [83].
Concerning serology, many studies have used the 
glycerophosphoryl diester phosphodiesterase (GlpQ) 
antigen expressed by members of the relapsing fever 
borreliae, but absent from  B. burgdorferi  s.l. [84]. 
Assays based upon GlpQ will not be B. miyamotoi-spe-
cific, but in areas where other members of the relaps-
ing fever borreliae are not prevalent, such assays can 
be useful for population surveys and diagnosis on non-
acute infections [85]. Besides the difficulties of GlpQ 
assays to distinguish B. miyamotoi from other relapsing 
fever borreliae, it is noteworthy that homologous pro-
teins have been reported from both Klebsiella pneumo-
niae  and  Salmonella enterica  [86]. In addition to lack 
of specificity, other reported limitations with the GlpQ 
antigen-based approach have been poor diagnostic 
sensitivity, with ability to only detect 28 of 36 conva-
lescent samples from established cases [78].
As the use of vmps as antigens has also been explored 
for serodiagnosis [87], combinations of GlpQ together 
with mixtures of highly immunogenic vmps derived 
from  B. miyamotoi  have been evaluated as a way to 
improve the diagnostic efficacy [88]. This involved a 
comprehensive series of 182 PCR-confirmed Russian 
patients who were followed with sequential sera col-
lected over several months post-infection. Notably, 
combinations of antigens provided superior sensitiv-
ity and/or specificity, with diagnostic titres for IgM, 
which were reached from 11 to 20 days post-disease 
onset and for IgG, from 21 to 50 days. This study used 
blood donor controls and additionally, controls with 
tick-borne encephalitis recruited from the same geo-
graphical region together with controls without tick 
exposure. Use of the combined antigens resulted in a 
sensitivity of 94.7% and specificity of 96.6% for IgM 
from 11 to 20 days post clinical presentation, thus pro-
viding important improvements over previous assays 
[88]. Assessment of duration of serological reactiv-
ity in seven of the 182 patients, showed that the IgM 
response waned within a year, while half (4/7) remained 
seropositive for IgG a year following disease. All indi-
viduals had been prescribed antimicrobial therapy.
On a cautionary note, the C6 ELISA used for diagnos-
ing Lyme disease may additionally be positive in those 
infected by B. miyamotoi [69]. Furthermore, when using 
serological tests to detect B. miyamotoi in areas where 
multiple spirochaetes are endemic, the possibility of 
serological cross-reactivity between other relapsing 
fever borreliae such as  B. hermsii  should be kept in 
mind as this may obscure diagnosis [64,85].
Given the increasing recognition of co-infections among 
those with tick exposure, it might be prudent to take a 
more holistic approach and screen for a broader range 
of tick-borne pathogens than just borreliae [89]. Some 
diagnostic centres have taken this approach, but many 
do not yet have the resources for more comprehensive 
tick-borne pathogen screening.
Isolation of borreliae is always a challenge as these 
microbes are particularly fastidious to cultivate, 
requiring complex liquid medium. Isolation is typically 
confirmed by dark field microscopy. The Barbour–
Stoenner–Kelly (BSK) commercially-available medium 
(BSK-H) used for  B. burgdorferi  s.l. is unreliable for 
growth of relapsing fever spirochaetes (data not 
shown) and when used for  B. miyamotoi, is unable to 
sustain passage of this organism [90]. Growth of  B. 
miyamotoi  has been achieved using modifications of 
Kelly–Pettenkofer medium (MKP) [16,91] or in a varia-
tion of BSK described as BSK-M [4]. Other studies have 
used media modifications with inclusion of 50% serum 
in order to cultivate these spirochaetes [92].
Propagation of isolates has additionally been achieved 
using inoculation of SCID mice. Typically, these will 
show spirochaetes in blood films between 7 and 14 
days post-infection [34].
Treatment
Therapy for B. miyamotoi infection has typically followed 
guidelines used for treatment of Lyme borreliosis. Only 
a few cultivable strains have been recovered to date, 
restricting evaluation of different clinical management 
regimes. Moreover limited in vitro susceptibility testing 
has been undertaken to verify the efficacy of different 
therapeutic protocols [93]. Koetsveld and co-authors, 
noted resistance to amoxicillin  in vitro  (16–128 mg/L) 
using two isolates of  B. miyamotoi  [93]. Interestingly, 
this feature was also shared by the relapsing fever 
spirochaete  B. hermsii  that was assessed in parallel. 
Despite these  in vitro  findings, a patient treated with 
amoxicillin (and sultamicillin) responded without 
complications [80]. No treatment failures have been 
reported to date, thus it is probable that the hypoth-
esised susceptibility profile being analogous to the 
Lyme-associated species is supported. Standard meth-
ods are not applicable for evaluation of the suscep-
tibility testing of borreliae given their need for liquid 
cultivation, microaerophilic conditions and coupled 
with their slow mean generation time [94-96]. Akin to 
other members of the genus and spirochaetal infec-
tions in general, a proportion of patients may develop 
a Jarisch–Herxheimer reaction (JHR) associated with 
a sudden exacerbation of clinical signs upon onset of 
treatment [97]. Though reported, JHR does not appear 
frequently for cases of acute  B. miyamotoi  infection 
[2,74].
Future research directions
Much of the data so far arise from studies designed 
and funded to look either at tick-borne diseases or 
more specifically Lyme-associated borreliae. Though 
valuable, these studies might be biased and not reflect 
9www.eurosurveillance.org
some of the different ecological driving factors under-
pinning the observed epidemiology of this spirochaete. 
As such, we still need to more specifically address  B. 
miyamotoi epidemiology further. This is important both 
for risk assessment and for application of control/
intervention strategies. Indeed, many questions remain 
regarding our understanding of the pathobiology of 
this spirochaete (Table 3).
Future epidemiological studies need to consider the dif-
ferent genotypes of B. miyamotoi, particularly in areas 
of geographical overlap such as in Estonia and Russia 
[2,11]. Ability to assess the epidemiology of B. miyamo-
toi has been enhanced by the development of several 
multiplex PCR diagnostic methods providing a more 
cost-effective means for high throughput screening of 
samples [6,82,83]. These approaches, which are tai-
lored to detect genotypes already described, however 
run the risk of missing hitherto undescribed variants.
Indeed, while three genotypes of  B. miyamo-
toi  (American, Asian and European) have been 
previously described, each associated with different 
tick vectors (Table 2) [3], recent studies have found more 
diversity within the  B. miyamotoispecies [10,12,28]. 
Future studies may shed light on how diverse  B. miy-
amotoi  genotype strains and variants behave. For 
example, it has not been comprehensively addressed 
if each of the B. miyamotoi genotypes or variants and 
their respective tick hosts are equally competent for 
transovarial transmission. Our knowledge to date is 
based upon studies that typically have only assessed 
one strain and tick species [33,54]. This information is 
currently extrapolated to others, but not underpinned 
by rigorous scientific enquiry.
Despite larger diversity recognised among  B. miy-
amotoi  strains, the species appears to be less 
heterogeneous than the  B. burgdorferi  s.l. complex, 
for which representatives sympatrically overlap with B. 
miyamotoi. Although it needs to be evaluated how 
strict new  B. miyamotoi  variants are to certain tick 
species, the variants identified to date have been found 
to be generally restricted to separate tick species, 
supporting the idea that, like for other B. miyamotoispi-
rochaetes, ticks still serve as both reservoirs and vec-
tors for these [19]. Conversely, for the Lyme-associated 
species, ticks act mainly as vectors, while a plethora of 
vertebrates serve as reservoirs for horizontal infection, 
potentially driving diversity within this complex.
This being said, vertebrates also play a role in the 
ecology of  B. miyamotoi. In this respect, it is notable 
that high infection rates were reported in turkeys [41]. 
Studies of avian vertebrates and their role in the ecol-
ogy of  B. miyamotoihave largely excluded ground for-
aging gallinaceous species, which is surprising given 
their established role as a reservoir for  B. burgdor-
feri s.l [98]. Looking into these avian species may pro-
vide missing pieces of the jigsaw of understanding the 
ecological niche of this spirochaete.
Coinfections by  B. burgdorferi  and  B. miyamotoi  have 
been observed in both vertebrates and ticks. Within 
ticks, a further level of complexity arises from the grow-
ing appreciation of how different microbes might facili-
tate survival or transmission. An ecological synergy 
is proposed whereby  B. burgdorferi  s.l. and  Babesia 
microti  benefit each other [99], but currently we have 
no knowledge of such interactions for  B. miyamotoi. 
Importantly, we should consider how other patho-
gens present within ticks (including other Borrelia) will 
Table 2
Global distribution of Borrelia miyamotoi clades and known vectors as at 2018
Tick species Geographical range
Predominating Borrelia 
miyamotoi genotype 
 
(co-occurring variants)
Tick feeding 
preference References
Ixodes persulcatus Baltic to Far East Asian Generalist [2,11]
Ixodes pavlovskyi Western Siberia and Far East Asian Ground foraging birds, small mammals [4,104]
Ixodes ovatus South East Asia
Asian 
 
(new Asian variant)
Generalist [4,10]
Ixodes ricinus
Northern Sweden to north 
Africa, Ireland to Ural in 
Russia
European 
 
(Asian)
Generalist [11,15]
Ixodes scapularis North-eastern and upper Midwestern United States American Generalist [33,44,54]
Ixodes pacificus Pacific coast of United States
American 
 
(new American variant)
Generalist [44]
Ixodes dentatus Eastern United States American Rabbits, hares Birds (larvae and nymphs) [31]
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influence the survival, persistence and transmissibility 
of B. miyamotoi.
To anticipate human infection, consideration of the 
tick species likely to be encountered is important. An 
example might be the detected presence of B. miyamo-
toi within I. dentatus ticks that preferentially feed upon 
birds or lagomorphs and thus present a reduced risk 
of human infection [31]. Such information would enable 
instigation of risk prediction, modelling and targeted 
intervention approaches where justified.
Blood transfusion has been hypothesised as a risk fac-
tor for  B. miyamotoi  infection. Experimental studies 
have demonstrated the ability of  B. miyamotoi  to 
survive under conditions used for storage of blood 
transfusion products [100], raising concern that this 
could provide an additional source of infection (Table 
3). Though theoretically possible, clinical cases pre-
senting with acute signs, typically fever and associated 
non-specific influenza-like features, unlikely would 
present to donate blood [101]. Quantification of the 
numbers of spirochaetes present during human infec-
tion suggests that levels peak at ca 103−104  B. miy-
amotoi  copies per mL during the second to third day 
of illness, then rapidly wane until day eight [22]. These 
authors suggested that PCR diagnosis was unreliable 
after the fourth day of clinical signs which would sug-
gest low risk of transfusion related infection.
An enigma of our current understanding is why we fail 
to see a correlation between clinical cases of  B. miy-
amotoiinfection and tick infection prevalence. Human 
cases have occurred in some areas with relatively low 
tick infection prevalence, like Yekaterinburg, Russia, 
while in other countries or areas with higher prevalence 
in ticks, such as Mongolia or Hannover in Germany, 
no cases were reported. The reasons are likely to be 
multifactorial. Tick factors such as feeding preferences 
or the role of vertebrate hosts in intensifying or nega-
tively impacting transmission could perhaps account 
for the observations. Another explanation might be 
differential virulence in humans of the strains involved, 
as it remains to be solved if different strains/genotypes 
show differential virulence. Last, the absence of an evi-
dent relation between tick and human infection rates 
could also possibly result from lack of diagnostic abil-
ity, proximity to those with active research interest in 
tick-borne disease, or cases missed due to unspecific 
symptoms. The clinical features of B. miyamotoi indeed 
lack a diagnostic hallmark, and can potentially be 
misdiagnosed as granulocytic anaplasmosis [77,102]. 
Given these difficulties to recognise  B. miyamo-
toi infections, it is likely that cases are under-reported.
While spontaneous resolution of an infection with  B. 
miyamotoi can occur without antimicrobial intervention 
[69,103], some clinical studies have noted severe infec-
tion, with considerable proportions of cases being 
hospitalised (24% [78]). Because when cases are 
diagnosed, they are likely to be promptly treated, the 
long-term consequences of human infection remain 
to be determined. While case studies of immunocom-
promised individuals report notable clinical features 
[64,72-74], the other risk factors that might influence 
the clinical progression towards disease are also not 
clear. Future detailed epidemiological studies of cases 
detected will enable a more complete clinical picture 
to unfold.
We also need to be aware of unusual presentations 
resulting from potential co-infection. The areas report-
ing cases are likely endemic for a variety of different 
tick-borne diseases. Clinically, presence of one tick-
borne pathogen can obscure the concomitant presence 
of another. Consequently, it is a priority that those sus-
pected of  B. miyamotoiinfection be also comprehen-
sively screened for other tick-borne pathogens.
Diagnostic methods are nevertheless still widely con-
sidered ‘research tests’ and thus not generally avail-
able in more routine clinical settings. When these are 
possible, a delay in considering B. miyamotoi infection 
might further complicate their interpretation, due to the 
Table 3
Unanswered questions regarding the pathobiology of Borrelia miyamotoi, 2018
What is the global epidemiological picture of B. miyamotoi infection?
Are the different spirochaetal variants restricted among certain tick species?
What is the ecology of this spirochaete?
What is the contribution of high incidence vertebrate species such as wild turkeys towards maintaining the ecological niche for this 
spirochaete?
What are the consequences of other pathogens present within ticks (including other Borrelia) upon the survival, persistence and 
transmissibility of B. miyamotoi?
Do different strains show differential virulence within susceptible species?
What are the full range of clinical consequences within humans?
What are human risk factors for development of clinical disease above and beyond being immunocompromised?
Does blood transfusion present a substantive risk for infection?
What is the best diagnostic approach to take, using which sample types and at what time point during infection?
What is the best regime for therapeutic management of cases?
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poorly delineated clinical course of human infection. 
A further problem may be the variability of strains 
encountered which may affect diagnostic results.
Another problem relates to what the most appropri-
ate diagnostic sample is. Ticks removed from patients 
have limited diagnostic value in that transmission may 
not have occurred and this might only be one of sev-
eral ticks that might have bitten the individual in ques-
tion. During acute infection, blood samples are a key 
sample to collect, however samples should be taken as 
early as possible and certainly before commencement 
of antimicrobial therapy. Collection of CSF is valuable 
in cases showing neurological features. This might 
require concentration of the specimen to improve diag-
nostic sensitivity [72,74]. Serum samples for serologi-
cal investigation should be collected at all stages, with 
early sera used for assessment of seroconversion or 
increasing titre, and later samples for retrospective 
studies of prior exposure.
As for the therapeutic management of cases, a more 
comprehensive  in vitro  evaluation will be possible to 
guide this, once more isolates become available repre-
senting the diversity within this species.
Conclusion
Our understanding of B. miyamotoi and its ecology and 
infection potential have only recently started to unfold. 
The incidence of  B. miyamotoi  infection in humans is 
poorly explored, hampered by the lack of awareness 
and appropriate diagnostics. Our understanding of 
the clinical features of infection currently suggest a 
relatively mild infectious course without long-lasting 
sequelae for the majority of infected individuals, but 
with the caveat of being able to cause severe disease 
in the immunocompromised [72,74,86]. Current inci-
dence is likely to be grossly under-reported, suggested 
by predicted tick bite exposure and tick prevalence 
data, as well as through the absence of a clinical pres-
entation hallmark, making assessment of the impact of 
infection challenging.
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